TR199902890T2 - Omeprazolün farmasötik formülasyonu - Google Patents

Omeprazolün farmasötik formülasyonu

Info

Publication number
TR199902890T2
TR199902890T2 TR1999/02890T TR9902890T TR199902890T2 TR 199902890 T2 TR199902890 T2 TR 199902890T2 TR 1999/02890 T TR1999/02890 T TR 1999/02890T TR 9902890 T TR9902890 T TR 9902890T TR 199902890 T2 TR199902890 T2 TR 199902890T2
Authority
TR
Turkey
Prior art keywords
omeprazole
active ingredient
alkaline salt
enantiomer
core material
Prior art date
Application number
TR1999/02890T
Other languages
English (en)
Inventor
Erickson Magnus
Josefsson Lars
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199902890(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of TR199902890T2 publication Critical patent/TR199902890T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Aktif maddesini omeprazol, omeprazol'ün alkali bir tuzu, omeprazol'ün (-)-enantiomeri ve omeprazol'ün (-)-enantiomerinin alkali bir tuzunun olusturdugu gruptan seçilmis bir bilesigin olusturdugu enterik (bagirsaklara uygun) kaplamali agizdan alinan farmasötik bir formül ki, burada formülün aktif maddesi ve istege bagli olarak alkali reaksiyona giren bir bilesik çekirdek malzemesini olusturur, aktif madde bir baglama ajani olabilen farmasötik olarak uygun bir katki maddesinin ve söz konusu çekirdek malzemesi üzerindeki bir ayirma tabakasinin ve bir enterik kaplama tabakasinin karisimindan olusmaktadir. Farmasötik formüllerin imalatinda spesifik bir bulanma noktasi olan düsük viskoziteli bir hidroksipropil metilselüloz (HPMC) kullanilmaktadir. Bundan baska, bu basvuruda istem yapilan formüllerin hazirlanmasi ve ilaç olarak kullanimlari için gereken islemlerde tarif ediliyor.
TR1999/02890T 1997-05-28 1998-05-18 Omeprazolün farmasötik formülasyonu TR199902890T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
TR199902890T2 true TR199902890T2 (tr) 2000-02-21

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02890T TR199902890T2 (tr) 1997-05-28 1998-05-18 Omeprazolün farmasötik formülasyonu

Country Status (40)

Country Link
US (1) US6090827A (tr)
EP (1) EP0984773B1 (tr)
JP (1) JP4649001B2 (tr)
KR (1) KR100540721B1 (tr)
CN (1) CN1123338C (tr)
AR (1) AR012698A1 (tr)
AT (1) ATE234078T1 (tr)
AU (1) AU722879B2 (tr)
BR (1) BR9809484A (tr)
CA (1) CA2290531C (tr)
CZ (1) CZ298972B6 (tr)
DE (1) DE69812089T2 (tr)
DK (1) DK0984773T3 (tr)
DZ (1) DZ2494A1 (tr)
EE (1) EE03903B1 (tr)
EG (1) EG24044A (tr)
ES (1) ES2195342T3 (tr)
HR (1) HRP980260B1 (tr)
HU (1) HU229154B1 (tr)
ID (1) ID24654A (tr)
IL (1) IL132895A0 (tr)
IS (1) IS2856B (tr)
MA (1) MA26497A1 (tr)
MY (1) MY122298A (tr)
NO (1) NO328100B1 (tr)
NZ (1) NZ500886A (tr)
PL (1) PL194634B1 (tr)
PT (1) PT984773E (tr)
RS (1) RS49629B (tr)
RU (1) RU2207121C2 (tr)
SA (1) SA98190304B1 (tr)
SE (1) SE9702000D0 (tr)
SI (1) SI0984773T1 (tr)
SK (1) SK286625B6 (tr)
TN (1) TNSN98068A1 (tr)
TR (1) TR199902890T2 (tr)
TW (1) TW575435B (tr)
UA (1) UA71541C2 (tr)
WO (1) WO1998053803A1 (tr)
ZA (1) ZA984178B (tr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
MXPA02003762A (es) 1999-10-20 2002-09-30 Eisai Co Ltd Metodos para estabilizar compuestos basados en benzimidazol.
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
RU2359671C2 (ru) * 2003-01-29 2009-06-27 Такеда Фармасьютикал Компани Лимитед Способ получения препарата с покрытием
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2324354T3 (es) * 2005-07-29 2009-08-05 Rottapharm S.P.A. Combinacion terapeutica de itriglumida e inhibidores de la bomba de protones en el tratamiento de trastornos gastrointestinales y relacionados.
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
CN103126998A (zh) * 2007-09-28 2013-06-05 西梯茜生命工学股份有限公司 一种固态分散体和含有埃索美拉唑的药物组合物
RU2477123C2 (ru) * 2008-03-28 2013-03-10 Феррер Интернасионал, С.А. Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
ES2195342T3 (es) 2003-12-01
TW575435B (en) 2004-02-11
HK1025744A1 (en) 2000-11-24
PL194634B1 (pl) 2007-06-29
BR9809484A (pt) 2000-06-20
SI0984773T1 (en) 2003-10-31
SA98190304B1 (ar) 2006-10-11
DK0984773T3 (da) 2003-07-07
HRP980260A2 (en) 1999-02-28
EE9900540A (et) 2000-06-15
CZ298972B6 (cs) 2008-03-26
DZ2494A1 (fr) 2003-01-25
WO1998053803A1 (en) 1998-12-03
KR100540721B1 (ko) 2006-01-10
EP0984773B1 (en) 2003-03-12
CZ420299A3 (cs) 2000-05-17
IS2856B (is) 2013-11-15
SK159099A3 (en) 2000-06-12
PL337237A1 (en) 2000-08-14
ZA984178B (en) 1998-11-30
YU60899A (sh) 2002-06-19
IS5245A (is) 1999-11-11
ATE234078T1 (de) 2003-03-15
TNSN98068A1 (fr) 2005-03-15
IL132895A0 (en) 2001-03-19
CA2290531A1 (en) 1998-12-03
HRP980260B1 (en) 2003-10-31
HU229154B1 (en) 2013-09-30
RU2207121C2 (ru) 2003-06-27
NO995809D0 (no) 1999-11-26
US6090827A (en) 2000-07-18
SK286625B6 (sk) 2009-02-05
UA71541C2 (uk) 2004-12-15
PT984773E (pt) 2003-07-31
CA2290531C (en) 2006-12-12
EP0984773A1 (en) 2000-03-15
SE9702000D0 (sv) 1997-05-28
JP4649001B2 (ja) 2011-03-09
RS49629B (sr) 2007-08-03
JP2002500665A (ja) 2002-01-08
MA26497A1 (fr) 2004-12-20
HUP0002182A2 (hu) 2002-05-29
AU7680398A (en) 1998-12-30
CN1123338C (zh) 2003-10-08
HUP0002182A3 (en) 2003-02-28
NZ500886A (en) 2001-11-30
MY122298A (en) 2006-04-29
CN1258217A (zh) 2000-06-28
NO995809L (no) 2000-01-28
ID24654A (id) 2000-07-27
EG24044A (en) 2008-04-13
KR20010013104A (ko) 2001-02-26
NO328100B1 (no) 2009-12-07
AR012698A1 (es) 2000-11-08
DE69812089D1 (de) 2003-04-17
AU722879B2 (en) 2000-08-10
EE03903B1 (et) 2002-12-16
DE69812089T2 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
TR199902890T2 (tr) Omeprazolün farmasötik formülasyonu
DK1124539T3 (da) Farmaceutisk formulering der omfatter omeprazol
ATE291901T1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
YU49236B (sh) Višejedinični dozni oblici u tabletama koji sadrže omeprazol i jednu njegovu alkalnu so ili jedan enantiomer omeprazola ili jednu njegovu alkalnu so
RU99126869A (ru) Фармацевтический препарат омепразола
PL357144A1 (pl) Nowe postaci dawki podstawionego benzimidazolu oraz sposoby ich zastosowania
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
NZ512683A (en) Taste-masked pharmaceutical particles that are suitable for making chewable tablets
YU50695A (sh) Obložena pesticidna sredstva, postupci za njihovo dobijanje i smese koje ih sadrže
EP0616802A4 (en) Oral preparation for release in lower digestive tracts.
SE8804628D0 (sv) New compounds
ES2024993A6 (es) Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
BG104757A (en) Pellets having a core coated with a lipid lowering agent and a polymer
WO2002062299A3 (en) Improved controlled release oral dosage form
DE50011819D1 (de) Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
TH39916B (th) สูตรผสมทางเภสัชกรรมโอมีพราโซล
KR960013372A (ko) 경구용 오메프라졸 제제
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it
SI8710680B (sl) Farmacevtski pripravki kislinsko labilnih substanc za oralno uporabo